ISRN NeurologyPub Date : 2014-01-27eCollection Date: 2014-01-01DOI: 10.1155/2014/151572
Margarida Florindo
{"title":"Inflammatory cytokines and physical activity in multiple sclerosis.","authors":"Margarida Florindo","doi":"10.1155/2014/151572","DOIUrl":"https://doi.org/10.1155/2014/151572","url":null,"abstract":"<p><p>Background. Besides the functional benefits, physical activity triggers a hormonal pattern of immunologic responses with an anti-inflammatory effect in individuals who suffer from multiple sclerosis. Purpose. To analyze the influence of physical activity on multiple sclerosis and identify the intensity threshold which triggers the anti-inflammatory physiological mechanism. Methodology. A systematic review was made on the databases Medline, PubMed, ScienceDirect, PloS, PEDro, and Web of Science. Studies from references of retrieved articles were also collected. The criteria included studies published in English and random studies referred to the inflammatory process, connected with physical activity in individuals with multiple sclerosis. The studies were methodologically analyzed by two reviewers according to PEDro scale. Results and Discussion. Five random control trial studies were identified. The results revealed that with physical activity there seems to have a modulation on anti-inflammatory cytokines which improve physical and cardiorespiratory performance. More investigation is required. Conclusions. Physical activity influences the quality of life and it seems to stimulate the presence of anti-inflammatory cytokines. With light physical activity the cellular activity is lower, while with moderate activity there seems to have more capacity to help in the resolution of an inflammatory situation. </p>","PeriodicalId":14626,"journal":{"name":"ISRN Neurology","volume":"2014 ","pages":"151572"},"PeriodicalIF":0.0,"publicationDate":"2014-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/151572","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32174775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ISRN NeurologyPub Date : 2014-01-22eCollection Date: 2014-01-01DOI: 10.1155/2014/861091
S Lamdhade, A Ashkanani, R Alroughani
{"title":"Prevalence of Anti-JC Virus Antibody in Multiple Sclerosis Patients in Kuwait.","authors":"S Lamdhade, A Ashkanani, R Alroughani","doi":"10.1155/2014/861091","DOIUrl":"https://doi.org/10.1155/2014/861091","url":null,"abstract":"<p><p>Background. Multiple sclerosis (MS) therapeutics entered a new era after the development of anti-JC virus (anti-JCV) antibody assay that assesses the risk of development of progressive multifocal leukoencephalopathy (PML) in patients treated with natalizumab. Objective. To determine the prevalence of anti-JCV antibody among MS patients in Kuwait. Methods. Using the national MS registry, demographics and disease characteristics of MS patients who were screened for anti-JC virus antibody were collected. The prevalence of anti-JCV antibody seropositivity and its association with demographic and disease characteristics were evaluated. Results. Out of 110 screened MS patients for anti-JCV antibodies, 65.5% were females. Mean age and disease duration were 29.23 ± 8.55 and 5.39 ± 5.04 years, respectively. 47.3% of patients were already on natalizumab and 52.7% of patients were screened for stratification to either natalizumab or a different Disease Modifying Therapy (DMT). The overall prevalence of anti-JC virus antibody was 40%. Gender (P = 0.69), disease duration (P = 0.11), and number of natalizumab infusions (P = 0.64) were not associated with seropositivity. Patients aged ≥30 years were more likely to be seropositive (P = 0.01). Conclusion. The prevalence of anti-JCV antibody is slightly lower than what is reported in published studies. Seropositivity was associated with an increasing age of MS patients. </p>","PeriodicalId":14626,"journal":{"name":"ISRN Neurology","volume":"2014 ","pages":"861091"},"PeriodicalIF":0.0,"publicationDate":"2014-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/861091","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32168835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ISRN NeurologyPub Date : 2014-01-22eCollection Date: 2014-01-01DOI: 10.1155/2014/956353
Khalid Abou Farha, Corine Baljé-Volkers, Wim Tamminga, Izaak den Daas, Sandra van Os
{"title":"Dopamine D2R Agonist-Induced Cardiovascular Effects in Healthy Male Subjects: Potential Implications in Clinical Settings.","authors":"Khalid Abou Farha, Corine Baljé-Volkers, Wim Tamminga, Izaak den Daas, Sandra van Os","doi":"10.1155/2014/956353","DOIUrl":"10.1155/2014/956353","url":null,"abstract":"<p><p>Dopamine D2 receptor agonists represent a first line treatment option in young patients with signs and symptoms of idiopathic Parkinson's disease. An association between the use of D2 receptor agonists in Parkinson's disease patients and heart failure has been reported. The identification of the underlying mechanism is needed to minimize the resultant cardiovascular morbidity. In a phase I clinical trial, a D2 receptor agonist (pramipexole) was administered to 52 healthy male subjects following a dose escalation scheme. Serial measurements of resting blood pressure, heart rate, and derived parameters including pulse pressure, pulsatile stress, and rate pressure product were analysed. Statistically significant and clinically relevant increases in most of the assessed parameters were found. Ten subjects were removed prematurely from the trial because of clinically significant increases in blood pressure and/or heart rate requiring immediate intervention with IV rescue medications including a selective β -1 blocker. The observed drug-related changes in vital signs were of clinical relevance and might explain some of the cardiovascular morbidity reported in patients receiving D2 receptor agonist in clinical settings. We suggest that the additional use of a β -1 blocking agent might mitigate the risk of cardiovascular morbidity among patients receiving long-term D2 receptor agonists. </p>","PeriodicalId":14626,"journal":{"name":"ISRN Neurology","volume":"2014 ","pages":"956353"},"PeriodicalIF":0.0,"publicationDate":"2014-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32168282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ISRN NeurologyPub Date : 2014-01-21eCollection Date: 2014-01-01DOI: 10.1155/2014/515716
Arshad Majid
{"title":"Neuroprotection in stroke: past, present, and future.","authors":"Arshad Majid","doi":"10.1155/2014/515716","DOIUrl":"10.1155/2014/515716","url":null,"abstract":"<p><p>Stroke is a devastating medical condition, killing millions of people each year and causing serious injury to many more. Despite advances in treatment, there is still little that can be done to prevent stroke-related brain damage. The concept of neuroprotection is a source of considerable interest in the search for novel therapies that have the potential to preserve brain tissue and improve overall outcome. Key points of intervention have been identified in many of the processes that are the source of damage to the brain after stroke, and numerous treatment strategies designed to exploit them have been developed. In this review, potential targets of neuroprotection in stroke are discussed, as well as the various treatments that have been targeted against them. In addition, a summary of recent progress in clinical trials of neuroprotective agents in stroke is provided. </p>","PeriodicalId":14626,"journal":{"name":"ISRN Neurology","volume":"2014 ","pages":"515716"},"PeriodicalIF":0.0,"publicationDate":"2014-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918861/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32163140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ISRN NeurologyPub Date : 2013-12-30eCollection Date: 2013-01-01DOI: 10.1155/2013/853737
Wai Yin Leung, Matthew B Jensen
{"title":"Histological quantification of angiogenesis after focal cerebral infarction: a systematic review.","authors":"Wai Yin Leung, Matthew B Jensen","doi":"10.1155/2013/853737","DOIUrl":"https://doi.org/10.1155/2013/853737","url":null,"abstract":"<p><p>Ischemic stroke is a leading cause of disability, and current treatments to improve recovery are limited. Part of the natural recovery process after brain injury is angiogenesis. The formation of new blood vessels around the infarct appears to be important for restoration of adequate perfusion to allow for healing of brain tissue. Many potential restorative treatments may affect, and be affected by, angiogenesis, so accurate quantification of this outcome is needed. We performed a systematic review of histological methods to quantify angiogenesis after cerebral infarction. We found reports of the use of a variety of histological and general and immunostaining techniques in conjunction with a variety of analysis methods. We found no direct comparison studies and concluded that more research is needed to optimize the assessment of this important stroke outcome. </p>","PeriodicalId":14626,"journal":{"name":"ISRN Neurology","volume":"2013 ","pages":"853737"},"PeriodicalIF":0.0,"publicationDate":"2013-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/853737","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32083858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Retrospective Comparison of Conventional versus Transverse Mini-Incision Technique for Carpal Tunnel Release.","authors":"Ismail Gülşen, Hakan Ak, Gökhan Evcılı, Ozlem Balbaloglu, Enver Sösüncü","doi":"10.1155/2013/721830","DOIUrl":"10.1155/2013/721830","url":null,"abstract":"<p><p>Background. In this retrospective study, we aimed to compare the results of two surgical techniques, conventional and transverse mini-incision. Materials and Methods. 95 patients were operated between 2011 and 2012 in Bitlis State Hospital. 50 patients were operated with conventional technique and 45 of them were operated with minimal transverse incision. Postoperative complications, incision site problems, and the time of starting to use their hands in daily activities were noted. Results. 95 patients were included in the study. The mean age was 48. 87 of them were female and 8 were male. There was no problem of incision site in both of the two surgical techniques. Only in one patient, anesthesia developed in minimal incision technique. The time of starting to use their hands in daily activities was 22,2 days and 17 days in conventional and minimal incision technique, respectively. Conclusion. Two surgical techniques did not show superiority to each other in terms of postoperative complications and incision site problems except the time of starting to use their hands in daily activities. </p>","PeriodicalId":14626,"journal":{"name":"ISRN Neurology","volume":"2013 ","pages":"721830"},"PeriodicalIF":0.0,"publicationDate":"2013-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32007003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ISRN NeurologyPub Date : 2013-11-20DOI: 10.1155/2013/829753
Pablo R Brumovsky
{"title":"VGLUTs in Peripheral Neurons and the Spinal Cord: Time for a Review.","authors":"Pablo R Brumovsky","doi":"10.1155/2013/829753","DOIUrl":"https://doi.org/10.1155/2013/829753","url":null,"abstract":"<p><p>Vesicular glutamate transporters (VGLUTs) are key molecules for the incorporation of glutamate in synaptic vesicles across the nervous system, and since their discovery in the early 1990s, research on these transporters has been intense and productive. This review will focus on several aspects of VGLUTs research on neurons in the periphery and the spinal cord. Firstly, it will begin with a historical account on the evolution of the morphological analysis of glutamatergic systems and the pivotal role played by the discovery of VGLUTs. Secondly, and in order to provide an appropriate framework, there will be a synthetic description of the neuroanatomy and neurochemistry of peripheral neurons and the spinal cord. This will be followed by a succinct description of the current knowledge on the expression of VGLUTs in peripheral sensory and autonomic neurons and neurons in the spinal cord. Finally, this review will address the modulation of VGLUTs expression after nerve and tissue insult, their physiological relevance in relation to sensation, pain, and neuroprotection, and their potential pharmacological usefulness. </p>","PeriodicalId":14626,"journal":{"name":"ISRN Neurology","volume":"2013 ","pages":"829753"},"PeriodicalIF":0.0,"publicationDate":"2013-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/829753","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31965950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ISRN NeurologyPub Date : 2013-11-06eCollection Date: 2013-01-01DOI: 10.1155/2013/134858
Fiona Costello
{"title":"The afferent visual pathway: designing a structural-functional paradigm of multiple sclerosis.","authors":"Fiona Costello","doi":"10.1155/2013/134858","DOIUrl":"10.1155/2013/134858","url":null,"abstract":"<p><p>Multiple sclerosis (MS) is a disease of the central nervous system (CNS) believed to arise from a dysfunctional immune-mediated response in a genetically susceptible host. The actual cause of MS is not known, and there is ongoing debate about whether this CNS disorder is predominantly an inflammatory versus a degenerative condition. The afferent visual pathway (AVP) is frequently involved in MS, such that one in every five individuals affected presents with acute optic neuritis (ON). As a functionally eloquent system, the AVP is amenable to interrogation with highly reliable and reproducible tests that can be used to define a structural-functional paradigm of CNS injury. The AVP has numerous unique advantages as a clinical model of MS. In this review, the parameters and merits of the AVP model are highlighted. Moreover, the roles the AVP model may play in elucidating mechanisms of brain injury and repair in MS are described. </p>","PeriodicalId":14626,"journal":{"name":"ISRN Neurology","volume":"2013 ","pages":"134858"},"PeriodicalIF":0.0,"publicationDate":"2013-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31913503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ISRN NeurologyPub Date : 2013-10-31eCollection Date: 2013-01-01DOI: 10.1155/2013/548240
Hye-Jung Choi, Carol Ewing Garber, Tae-Won Jun, Young-Soo Jin, Sun-Ju Chung, Hyun-Joo Kang
{"title":"Therapeutic effects of tai chi in patients with Parkinson's disease.","authors":"Hye-Jung Choi, Carol Ewing Garber, Tae-Won Jun, Young-Soo Jin, Sun-Ju Chung, Hyun-Joo Kang","doi":"10.1155/2013/548240","DOIUrl":"https://doi.org/10.1155/2013/548240","url":null,"abstract":"<p><p>Objective. The purpose of the study was to investigate the effects of a 12-week program of therapeutic Tai Chi on the motor function and physical function of idiopathic Parkinson's disease patients (PDs). Methods. The participants were 22 clinically stable PDs in Hoehn-Yahr stages 1-2 randomly assigned to a therapeutic Tai Chi group (TTC, N = 11) or a control group (CON, N = 9). Two subjects in control group did not complete the study for personal reasons. TTC was performed three days a week (60 min/session). Motor symptoms by the UPDRS were assessed, and tests of physical function were administered before and after the 12-week trial. Results. The TTC group, as compared to the CON group, showed changes in the mentation, behavior, mood, and motor scales of the UPDRS (P < 0.05, P < 0.01, resp.), with no significant main effects on the activities of daily living scale (ADL). However, there was a significant interaction between the time and intervention group on ADL (P < 0.05). There were no significant main effects for any of the physical function variables. There were significant interaction effects in balance and agility (P < 0.05, resp.). Conclusions. This study showed that TTC training had modest positive effects on the functional status of Parkinson's disease patients. </p>","PeriodicalId":14626,"journal":{"name":"ISRN Neurology","volume":"2013 ","pages":"548240"},"PeriodicalIF":0.0,"publicationDate":"2013-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/548240","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31918693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ISRN NeurologyPub Date : 2013-10-28eCollection Date: 2013-01-01DOI: 10.1155/2013/865827
Jenny Gu, Corinne E Fischer, Gustavo Saposnik, Tom A Schweizer
{"title":"Profile of cognitive complaints in vascular mild cognitive impairment and mild cognitive impairment.","authors":"Jenny Gu, Corinne E Fischer, Gustavo Saposnik, Tom A Schweizer","doi":"10.1155/2013/865827","DOIUrl":"https://doi.org/10.1155/2013/865827","url":null,"abstract":"<p><p>Objective. Vascular mild cognitive impairment (VaMCI) is differentiated from mild cognitive impairment (MCI) by the presence of vascular events such as stroke or small vessel disease. Typically, MCI and VaMCI patients present with subjective complaints regarding cognition; however, little is known about the specific nature of these complaints. We aimed to create a profile of subjective cognitive complaints in MCI and VaMCI patients with similar levels of objective cognitive performance. Methods. Twenty MCI and twenty VaMCI patients were recruited from a Memory Disorders Clinic in Toronto. Subjective cognitive complaints were assessed and categorized using the Neuropsychological Impairment Scale. Results. MCI and VaMCI patients achieved similar scores on measures of objective cognitive function (P > 0.100). However, the VaMCI group had more subjective complaints than the MCI group (P = 0.050), particularly in the critical items, cognitive efficiency, memory, and verbal learning domains of the Neuropsychological Impairment Scale. Conclusions. Our findings support the idea that VaMCI and MCI differ in their clinical profiles, independent of neuroimaging. VaMCI patients have significantly more subjective cognitive complaints and may be exhibiting particular deficits in memory, verbal learning, and cognitive efficiency. Our findings promote the need for further research into VaMCI-specific cognitive deficits. </p>","PeriodicalId":14626,"journal":{"name":"ISRN Neurology","volume":"2013 ","pages":"865827"},"PeriodicalIF":0.0,"publicationDate":"2013-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/865827","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31913504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}